Reuters -- Spain’s Grifols (GRLS.MC), embroiled in a $3.4 billion takeover bid to become the world’s third-largest haemoderivatives maker, posted a 3.7 percent rise in first-half sales, helped by strength at its Bioscience division.
Reuters -- Spain’s Grifols (GRLS.MC), embroiled in a $3.4 billion takeover bid to become the world’s third-largest haemoderivatives maker, posted a 3.7 percent rise in first-half sales, helped by strength at its Bioscience division.
